Supplementary MaterialsSupplementary document 1. (1st prescription) day was dipeptidyl peptidase-4 inhibitor (DPP-4i) in UT individuals (JMDC: 44.0%, MDV: 54.8%) and mixture therapy in PT individuals (74.6%, 81.1%). Many common combinations had been DPP-4i plus: biguanide (BG; 11.4%, 10.9%), sulfonylurea (SU; 8.4%, 11.0%) or BG+SU (7.8%, 9.1%). In UT or PT individuals from either data source … [Read more…]
Supplementary Materialsbiomolecules-10-00334-s001. treatment approach involving CFTR modulators and anti-infectives (i.e., tobramycin and/or 6K-F17) to improve their overall efficacy in CF patients. [6]. Prolonged infections have been linked to chronic inflammation in the CF lung [7,8], worsening the damage to lung tissue, and leading to eventual respiratory failure [9]. More than 2000 CF-causing mutations have been … [Read more…]
Data Availability StatementAll data analyzed in this study are included in this article. in this study in identifying p53 altered pathways. Our method could pave a new way of carrying out next generation pathway analysis. or other than the fact that some pathway could be highly involved in the experimental system being analyzed. The next … [Read more…]